Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Will resistance to ketolides develop in Streptococcus pneumoniae?

R Leclercq1

  • 1CHU de Caen, Service de Microbiologie, France. leclercq-r@chu-caen.fr

The Journal of Infection
|August 2, 2002
PubMed
Summary

Rising antibacterial resistance necessitates new treatments. Ketolides, like telithromycin, offer a novel solution for respiratory tract infections, effectively combating resistant pathogens without promoting further resistance.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In vitro activity of josamycin against Streptococcus pyogenes isolated from patients with upper respiratory tract infections in France.

Medecine et maladies infectieuses·2015
Same author

Unique blood culture for diagnosis of bloodstream infections in emergency departments: a prospective multicentre study.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2014
Same author

Outbreak in a haematology unit involving an unusual strain of glycopeptide-resistant Enterococcus faecium carrying both vanA and vanB genes.

The Journal of antimicrobial chemotherapy·2013
Same author

Aspergillus vertebral osteomyelitis in immunocompetent subjects: case report and review of the literature.

Infection·2013
Same author

Emergence of Staphylococcus aureus strains resistant to pristinamycin in Sfax (Tunisia).

Pathologie-biologie·2012
Same author

EUCAST expert rules in antimicrobial susceptibility testing.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2011

Area of Science:

  • Microbiology
  • Pharmacology
  • Infectious Diseases

Background:

  • Increasing resistance to macrolide, lincosamide, and streptogramin B (MLSB) antibacterials, particularly in Streptococcus pneumoniae, limits treatment options for respiratory tract infections (RTIs).
  • Development of novel antibacterial agents that do not select for resistance is crucial for preserving future antibacterial efficacy.

Purpose of the Study:

  • To introduce ketolides, a new class of antibacterials exemplified by telithromycin, as a potential solution for empirical treatment of RTIs.
  • To highlight the unique structural modifications of ketolides and their implications for overcoming MLSB resistance.

Main Methods:

  • Analysis of the chemical structure of ketolides, focusing on the keto function at position 3 and the C11,12-carbamate side chain.

Related Experiment Videos

  • Evaluation of ketolides' interaction with bacterial 23S rRNA and their binding affinity to ribosomes, including MLSB-resistant strains.
  • Assessment of ketolides' potential for resistance and cross-resistance selection in vitro and in vivo.

    • Main Results:

    • Ketolides possess a novel structure distinct from traditional macrolides, which prevents the induction of MLSB resistance in vitro.
    • The structural modifications enhance ketolides' binding to bacterial ribosomes, including those in MLSB-resistant strains.
    • Ketolides demonstrate intrinsic activity against respiratory pathogens, retain efficacy against resistant strains, and exhibit a low potential for selecting resistance.

    Conclusions:

    • Ketolides represent a new class of antibacterials with a unique mechanism of action effective against respiratory pathogens.
    • Their ability to avoid inducing MLSB resistance and retain activity against resistant strains makes them valuable for empirical RTI treatment.
    • Ketolides offer a promising therapeutic option with a low risk of resistance development, safeguarding future antibacterial efficacy.